12:00 AM
 | 
Nov 05, 2012
 |  BC Week In Review  |  Company News  |  Other News

Medtronic musculoskeletal news

The U.S. Senate Finance Committee completed its investigation of Medtronic and concluded that company officials influenced the content of articles in peer-reviewed scientific publications to present its bone repair product InFuse Bone Graft in the best possible light. The committee's report determined, among other findings, that Medtronic recommended omitting the discussion of adverse events possibly associated with the product in a 2005 publication, sought to emphasize pain in alternative treatments, wrote author responses to peer-review and wrote expert testimony to the FDA. The...

Read the full 392 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >